Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma

Toripalimab was approved by the NMPA as the first-line treatment for unresectable or metastatic melanoma, the 12th indication in the Chinese mainland.